Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.
At ADA, Breakthrough T1D-Funded Research Takes Center Stage
There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of the key takeaways from the conference.
Advancing Cures with Type 1 Diabetes Clinical Trials
May 20 is Clinical Trials Day, a day to raise awareness of clinical research and the people around the world who take part in trials.
50+ Years with Type 1: An Interview with Dr. George King
I got the privilege of interviewing George King, M.D., whose research is on diabetes complications. Breakthrough T1D has funded him since he was early in his career.
National DNA Day!
Aaron Michels, M.D., discovered that methyldopa—a therapy that has been used for 50 years to treat high blood pressure—may have a role in delaying T1D.
FDA Breakthrough Therapy Designation for TTP399—A Potential First-in-Class Adjunct Therapy in T1D
The FDA granted Breakthrough Therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for T1D.
Severe Low Blood Sugar: There’s a New Treatment Option
The FDA approved Zegalogue® (dasiglucagon) injection, for the treatment of severe hypoglycemia in children and adults with diabetes aged 6 and above.
Keeping Your Kidneys Healthier, For Longer
Normally, the kidneys filter waste and extra water out of your blood to make urine. When your kidneys are damaged, they can’t filter blood like they should.
Vertex Has a New Horizon: Curing Type 1 Diabetes
Vertex Pharmaceuticals will launch a clinical trial of VX-880, a stem cell-derived beta cell therapy in type 1 diabetes (T1D).
What We Can Be Proud Of in 2020
It’s been a tough year, to say the least. But there’s news that we can be proud of in type 1 diabetes research and advocacy. Really proud of.
